who is developing retatrutide 🚨 JUST RELEASED TODAY!!!! NEW PHASE 3 DATA Today, July 23, 2026, new Phase 3 retatrutide results were released, adding to what already one of the most interesting obesity drug Retatrutide Where to Get: Can

Diabetes resolved in 98.9% of patients undergoing biliopancreatic diversion or DS

Conclusion Real transformation isnt found in trendsits built through science, consistency, and care

Real-world comparative effectiveness studies have corroborated clinical trial findings

Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs

If lumps develop: These are usually localized swelling, not dangerous

Klinger, DBA, MS, RD, CPT Medical Reviewer Sylvia Klinger, DBA, MS, RD, CPT, is an internationally recognized nutrition expert who is relentlessly passionate about helping people fall in love with creating and enjoying deli